Baseline patient characteristics
| . | Number . |
|---|---|
| Age at time of alloBMT, y | 35.6 (range, 24.3-61.9) |
| Illness, n | |
| Hodgkin lymphoma | 10 |
| AML/myelodysplastic syndrome | 2 |
| Primary effusion lymphoma | 1 |
| Diffuse large B cell lymphoma | 1 |
| Stem cell donor, n | |
| Related haploidentical | 10 |
| Degree of mismatch | |
| 6 of 10 | 1 |
| 5 of 10 | 9 |
| Matched unrelated | 2 |
| Mismatched unrelated | 2 |
| Degree of mismatch | |
| 9 of 10 | 1 |
| 7 of 10 | 1 |
| Stem cell source, n | |
| Bone marrow | 12 |
| Peripheral blood | 2 |
| Checkpoint inhibitory history | |
| Checkpoint inhibitor(s) received, n | |
| Nivolumab | 8 |
| Ipilimumab | 3 |
| Pembrolizumab | 2 |
| Ipilimumab and nivolumab | 1 |
| No. of infusions, median | 6 (range, 3-24) |
| Median time between last checkpoint inhibitor infusion and stem cell infusion, d | 42 (range, 18-231) |
| Response to checkpoint inhibitor, n | |
| Complete response | 8 |
| Partial response | 6 |
| . | Number . |
|---|---|
| Age at time of alloBMT, y | 35.6 (range, 24.3-61.9) |
| Illness, n | |
| Hodgkin lymphoma | 10 |
| AML/myelodysplastic syndrome | 2 |
| Primary effusion lymphoma | 1 |
| Diffuse large B cell lymphoma | 1 |
| Stem cell donor, n | |
| Related haploidentical | 10 |
| Degree of mismatch | |
| 6 of 10 | 1 |
| 5 of 10 | 9 |
| Matched unrelated | 2 |
| Mismatched unrelated | 2 |
| Degree of mismatch | |
| 9 of 10 | 1 |
| 7 of 10 | 1 |
| Stem cell source, n | |
| Bone marrow | 12 |
| Peripheral blood | 2 |
| Checkpoint inhibitory history | |
| Checkpoint inhibitor(s) received, n | |
| Nivolumab | 8 |
| Ipilimumab | 3 |
| Pembrolizumab | 2 |
| Ipilimumab and nivolumab | 1 |
| No. of infusions, median | 6 (range, 3-24) |
| Median time between last checkpoint inhibitor infusion and stem cell infusion, d | 42 (range, 18-231) |
| Response to checkpoint inhibitor, n | |
| Complete response | 8 |
| Partial response | 6 |